<DOC>
	<DOC>NCT02598934</DOC>
	<brief_summary>This study will evaluate whether an early positive response to once-monthly oral ibandronate in treatment-naive participants with postmenopausal osteoporosis is predictive of efficacy later in treatment. The anticipated time on study treatment is 6 months, and the target sample size is 360 individuals.</brief_summary>
	<brief_title>A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Women newly diagnosed with postmenopausal osteoporosis Naive to prior bisphosphonate therapy Inability to stand or sit upright for at least 60 minutes Inability to swallow a tablet whole Hypersensitivity to any component of ibandronate Hormone (estrogen) replacement therapy within last 3 months, or will start on therapy within next 6 months Other osteoporosis drug within last 3 months Malignant disease diagnosed within previous 10 years, except resected basal cell cancer</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>